Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00188708
Status:
COMPLETED
Last Update Posted:
2024-03-18
First Post:
2005-09-12
Brief Title:
Effect of Casodex on Tumour Hypoxia - Prostate Cancer
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
A Study of the Effect of Neoadjuvant Bicalutamide Casodex on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancers in common with many other tumours are often hypoxic that is they have low levels of oxygen It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment One previous study has suggested that hormone therapy such as Casodex may improve the prostate oxygen level This study is designed to test that finding
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| National Cancer Inst of Canada | None | None | None |